Bayer invests USD 2.2 billion as Bayer stock sits 16.75 percent below its high

Published on 10/06/2026 at 13:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second quarter sales reached EUR 10.872 billion, up 2.20 percent. Bayer stock trades at EUR 44.89 on October 6, 2026 versus EUR 44.11, plus 1.77 percent.

Aquarellbild einer Industriestadt-Skyline am Flussufer mit sanften Farbverläufen — Bayer AG (DE000BAY0017): Aquarellmalerei der Skyline von Leverkusen mit Industrieanlagen am Rhein, Illustration mit AI erstellt.

Bayer (ISIN DE000BAY0017) was trading at EUR 44.89 at Lang & Schwarz on October 6, 2026 at 1:12 p.m. CEST, up 1.77 percent versus the prior close of EUR 44.11. On October 2, Bayer announced plans for a USD 2.2 billion pharmaceutical manufacturing site in New Albany, Ohio, making the US expansion the latest concrete investment signal for the group.

Ohio investment sets a long runway

According to Bayer on October 2, 2026, the modular campus will combine drug substance and drug product manufacturing. The first module is expected to become operational in 2031, while a second module for finished drug products is planned to follow in 2034.

The investment extends Bayer's US manufacturing footprint at a time when its pharmaceutical business is emphasizing oncology, cardiovascular and renal care. The long construction timetable also means the project is a capacity and pipeline commitment rather than an immediate earnings driver.

Second quarter growth stays measurable

In the second quarter of 2026, Bayer reported group sales of EUR 10.872 billion, up 2.20 percent on a currency and portfolio adjusted basis. EBITDA before special items increased 1.90 percent to EUR 2.144 billion, while core earnings per share rose 16.70 percent.

Those figures come from Bayer in its second quarter 2026 reporting. The combination of higher sales and faster growth in EBITDA before special items gives investors a clearer operating reference point for the Ohio project than the investment headline alone.

Analyst targets remain above the quote

A September 2026 survey published by finanzen.net listed five analyst assessments, all at Buy or Overweight, with an average price target of EUR 62.60. That target stands 39.45 percent above the Lang & Schwarz price of EUR 44.89, although the survey reflects assessments made in September rather than a new October target.

Stock remains below yearly high

Bayer stock remained 16.75 percent below its EUR 53.92 52-week high on October 6, 2026, despite the intraday gain against the EUR 44.11 prior close. The reference market value was EUR 44.2 billion, while the next scheduled third-quarter 2026 results and investor video call are both set for November 3, 2026, according to Bayer.

The further course of trading is shown by the continuously updated real-time quote of Bayer stock.